The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.
Browse Complete Report Details:
F. Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity
The diabetic retinopathy is a severe kind of disorder that has accounted for the majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and approvals from the National Institute of Health (NIH).
North America to Emerge Dominant in the Forecast Period
The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years. The Retinal Disease Therapeutics Market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years
More Trending Topics from Future Business Insights: